Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
US Market
Holding ATHE?
Track your performance easily

Alterity Therapeutics (ATHE) Stock Price & Analysis

246 Followers

ATHE Stock Chart & Stats


Financials

Annual

Ownership Overview

0.00%0.01%0.07%99.92%
0.00%
Insiders
0.07% Other Institutional Investors
99.92% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

ATHE FAQ

What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $1.01 and its highest was $5.41 in the past 12 months.
    What is Alterity Therapeutics Ltd’s market cap?
    Currently, no data Available
    When is Alterity Therapeutics Ltd’s upcoming earnings report date?
    Alterity Therapeutics Ltd’s upcoming earnings report date is Feb 27, 2025 which is in 161 days.
      How were Alterity Therapeutics Ltd’s earnings last quarter?
      Alterity Therapeutics Ltd released its earnings results on Feb 28, 2024. The company reported -$0.515 earnings per share for the quarter, missing the consensus estimate of -$0.107 by -$0.408.
        Is Alterity Therapeutics Ltd overvalued?
        According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Alterity Therapeutics Ltd pay dividends?
          Alterity Therapeutics Ltd does not currently pay dividends.
          What is Alterity Therapeutics Ltd’s EPS estimate?
          Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Alterity Therapeutics Ltd have?
          Alterity Therapeutics Ltd has 8,867,227 shares outstanding.
            What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
            Alterity Therapeutics Ltd reported an EPS of -$0.515 in its last earnings report, missing expectations of -$0.107. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
              Currently, no hedge funds are holding shares in ATHE
              ---

              Alterity Therapeutics Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -50.57%
              12-Months-Change

              Fundamentals

              Return on Equity
              -102.86%
              Trailing 12-Months
              Asset Growth
              -29.40%
              Trailing 12-Months

              Company Description

              Alterity Therapeutics Ltd

              Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Apellis Pharmaceuticals
              SELLAS Life Sciences Group
              Cellectar Biosciences
              Moleculin Biotech
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis